Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol

Conditions: Major Depressive Disorder Interventions: Drug: Solriamfetol 300 mg; Drug: Placebo Sponsors: Axsome Therapeutics, Inc. Recruiting

Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials